Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 1.00 |
| ▸ | CACNA2D1 | P54289 | 5/20 | 0.66 |
| ▸ | CACNB1 | Q02641 | 5/20 | 0.66 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.66 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.66 |
| ▸ | HRH1 | P35367 | 4/20 | 0.61 |
| ▸ | DRD3 | P35462 | 3/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.61 |
| ▸ | HRH2 | P25021 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.61 |
| ▸ | HTR2B | P41595 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.61 |
| ▸ | TEK | Q02763 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | GPX4 | P36969 | 2/20 | 0.60 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.57 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4150496 | 0.98 | SLC6A9 (0.97) | SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL4136017 | 0.96 | SLC6A9 (0.91) | SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL28935916 | 0.96 | SLC6A9 (0.91) | SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C | |
| Hydrochloric Acid SCHEMBL4140455 | 0.94 | SLC6A9 (0.89) | SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL1691475 | 0.85 | SLC6A9 (0.74) | SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL10929636 | 0.84 | SLC6A9 (0.72) | SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL4144090 | 0.84 | SLC6A9 (0.72) | SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL27520894 | 0.81 | HRH1 (0.72) | SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL14859743 | 0.81 | SLC6A9 (0.67) | SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL4139140 | 0.81 | SLC6A9 (0.68) | SLC6A9CACNA2D1CACNB1CACNA1BCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735383-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2014-05-27 | — | — | US | claimed |
| EP-2041088-B1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC (US) | 2014-01-08 | — | — | EP | claimed |
| US-20120195985-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2012-08-02 | — | — | US | claimed |
| US-20090227595-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | HITCHCOCK STEPHEN | 2009-09-10 | — | — | US | claimed |
| US-7538114-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2009-05-26 | — | — | US | claimed |
| EP-2041088-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen Inc. (US) | 2009-04-01 | — | — | EP | claimed |
| WO-2008002583-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2008-01-03 | — | — | WO | claimed |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | AMGEN INC. | 2008-01-03 | — | — | US | claimed |
| US-9663476-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2947067-A1 | Glycine transporter-1 inhibitors | Amgen, Inc (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2565183-A1 | Glycine transporter-1 inhibitors | Amgen Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227595-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC7A11, SLC6A5 | SLC6A9 8/4885CACNA2D1 3216/4885CACNB1 2118/4885 |
| US-20120195985-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC6A5, SLC1A2 | SLC6A9 6/4885CACNA2D1 3030/4885CACNB1 1621/4885 |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | SLC18A2, SLC7A11, SLC6A5 | SLC6A9 8/4885CACNA2D1 3216/4885CACNB1 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.